Cargando…
Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial
Remimazolam tosilate (RT) is a new short-acting γ-aminobutyric acid A (GABAA) receptors agonist. However, its optimal use mode and dosage still remain unclear. This study aimed to examine the safety and effectiveness of the combination of RT and propofol in gastroscopy. This was a prospective, singl...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264591/ https://www.ncbi.nlm.nih.gov/pubmed/37324493 http://dx.doi.org/10.3389/fphar.2023.1124667 |
_version_ | 1785058355232899072 |
---|---|
author | Wang, Chunyan Gao, Yangzheng Li, Jie Zhang, Linlin Li, Qing Li, Yize Lu, Yuechun Sun, Jiangang Zhang, Yang Cheng, Yaobei Zhang, Shidong Wang, Guolin Yu, Yonghao |
author_facet | Wang, Chunyan Gao, Yangzheng Li, Jie Zhang, Linlin Li, Qing Li, Yize Lu, Yuechun Sun, Jiangang Zhang, Yang Cheng, Yaobei Zhang, Shidong Wang, Guolin Yu, Yonghao |
author_sort | Wang, Chunyan |
collection | PubMed |
description | Remimazolam tosilate (RT) is a new short-acting γ-aminobutyric acid A (GABAA) receptors agonist. However, its optimal use mode and dosage still remain unclear. This study aimed to examine the safety and effectiveness of the combination of RT and propofol in gastroscopy. This was a prospective, single-blind, randomized, multicenter, parallel-group study. All eligible 256 patients were randomized into the following 3 groups. Patients were anesthetized with propofol (Group P), RT (Group R) or the combination of RT and propofol (Group RP). The primary efficacy endpoints were: body movement score; satisfaction of gastroscopy doctors; success rate of sedation and effects on sleep status. Sedation induction time, time to be fully alert and adverse events were also recorded. The probability of complete immobility was lower in group R (33.73%) than in group P (86.67%) and RP (83.13%). The rate of doctors’ satisfaction was much lower in group R (28.92%) than in group P (77.78%) and RP (72.29%). The success rate of sedation and sleep outcome score has no difference in the three groups. The time to adequate sedation was longer in group RP (77.27 ± 18.63 s) than in group P (64.47 ± 24.36 s), but much shorter than that in group R (102.84 ± 46.43s). The time to be fully alert was shorter in group R (6.30 ± 1.52 min) and RP (6.54 ± 1.13 min) than in group P (7.87 ± 1.08 min). The proportion of sedative hypotension was significantly higher in group P (41.11%) than in group R (1.20%) and group RP (3.61%) (p < 0.001). The incidence of respiratory depression was much higher in group P (17.78%) than in group R (no patient) and group RP (1.2%). The incidence of adverse events was lower in groups R (4.82%) and RP (9.64%) than in group P (31.11%). The combination of RT and propofol takes effect quickly, makes patients alert quickly, provides a sufficient depth of sedation, reduces body movement, does not inhibit circulation and respiratory function, does not affect sleep, and is the preferred mode for gastroscopy doctors and anesthesiologists. |
format | Online Article Text |
id | pubmed-10264591 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102645912023-06-15 Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial Wang, Chunyan Gao, Yangzheng Li, Jie Zhang, Linlin Li, Qing Li, Yize Lu, Yuechun Sun, Jiangang Zhang, Yang Cheng, Yaobei Zhang, Shidong Wang, Guolin Yu, Yonghao Front Pharmacol Pharmacology Remimazolam tosilate (RT) is a new short-acting γ-aminobutyric acid A (GABAA) receptors agonist. However, its optimal use mode and dosage still remain unclear. This study aimed to examine the safety and effectiveness of the combination of RT and propofol in gastroscopy. This was a prospective, single-blind, randomized, multicenter, parallel-group study. All eligible 256 patients were randomized into the following 3 groups. Patients were anesthetized with propofol (Group P), RT (Group R) or the combination of RT and propofol (Group RP). The primary efficacy endpoints were: body movement score; satisfaction of gastroscopy doctors; success rate of sedation and effects on sleep status. Sedation induction time, time to be fully alert and adverse events were also recorded. The probability of complete immobility was lower in group R (33.73%) than in group P (86.67%) and RP (83.13%). The rate of doctors’ satisfaction was much lower in group R (28.92%) than in group P (77.78%) and RP (72.29%). The success rate of sedation and sleep outcome score has no difference in the three groups. The time to adequate sedation was longer in group RP (77.27 ± 18.63 s) than in group P (64.47 ± 24.36 s), but much shorter than that in group R (102.84 ± 46.43s). The time to be fully alert was shorter in group R (6.30 ± 1.52 min) and RP (6.54 ± 1.13 min) than in group P (7.87 ± 1.08 min). The proportion of sedative hypotension was significantly higher in group P (41.11%) than in group R (1.20%) and group RP (3.61%) (p < 0.001). The incidence of respiratory depression was much higher in group P (17.78%) than in group R (no patient) and group RP (1.2%). The incidence of adverse events was lower in groups R (4.82%) and RP (9.64%) than in group P (31.11%). The combination of RT and propofol takes effect quickly, makes patients alert quickly, provides a sufficient depth of sedation, reduces body movement, does not inhibit circulation and respiratory function, does not affect sleep, and is the preferred mode for gastroscopy doctors and anesthesiologists. Frontiers Media S.A. 2023-05-31 /pmc/articles/PMC10264591/ /pubmed/37324493 http://dx.doi.org/10.3389/fphar.2023.1124667 Text en Copyright © 2023 Wang, Gao, Li, Zhang, Li, Li, Lu, Sun, Zhang, Cheng, Zhang, Wang and Yu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wang, Chunyan Gao, Yangzheng Li, Jie Zhang, Linlin Li, Qing Li, Yize Lu, Yuechun Sun, Jiangang Zhang, Yang Cheng, Yaobei Zhang, Shidong Wang, Guolin Yu, Yonghao Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title | Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title_full | Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title_fullStr | Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title_full_unstemmed | Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title_short | Safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
title_sort | safety and effectiveness of the combination of remimazolam tosilate and propofol in gastroscopy: a multicenter, randomized controlled, single-blind clinical trial |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264591/ https://www.ncbi.nlm.nih.gov/pubmed/37324493 http://dx.doi.org/10.3389/fphar.2023.1124667 |
work_keys_str_mv | AT wangchunyan safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT gaoyangzheng safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT lijie safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT zhanglinlin safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT liqing safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT liyize safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT luyuechun safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT sunjiangang safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT zhangyang safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT chengyaobei safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT zhangshidong safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT wangguolin safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial AT yuyonghao safetyandeffectivenessofthecombinationofremimazolamtosilateandpropofolingastroscopyamulticenterrandomizedcontrolledsingleblindclinicaltrial |